Last updated: October 15, 2026
Mircette is a legacy combined oral contraceptive containing desogestrel and ethinyl estradiol. Its commercial value has shifted from branded sales to low-cost generic supply. The product is no longer a meaningful branded growth asset in the United States, and no material standalone Mircette revenue is publicly reported. Current competition is based on generic desogestrel/ethinyl estradiol products, pharmacy access, price, and formulary placement rather than patent exclusivity.
What is Mircette and how does it compete?
Mircette is a 28-day oral contraceptive regimen that combines:
| Product characteristic |
Mircette |
| Active ingredients |
Desogestrel and ethinyl estradiol |
| Standard strength |
Desogestrel 0.15 mg and ethinyl estradiol 0.02 mg |
| Low-dose phase |
Ethinyl estradiol 0.01 mg during the final active-hormone interval |
| Dosage form |
Oral tablet |
| Therapeutic category |
Combined hormonal contraceptive |
| Original commercial sponsor |
Organon |
| Primary market |
United States |
| Main substitutes |
Kariva and generic desogestrel/ethinyl estradiol tablets |
| Current commercial position |
Legacy product with generic substitution |
Mircette was differentiated by reducing the hormone-free interval compared with many conventional 21-day combined oral contraceptives. The product’s commercial distinction was regimen design, not a new molecular entity.
Kariva is a branded generic version associated with the same desogestrel/ethinyl estradiol regimen. Other suppliers have marketed equivalent or therapeutically substitutable products under abbreviated new drug applications. The FDA-approved labeling identifies the product as an oral contraceptive indicated for pregnancy prevention in women who elect to use oral contraception.[1]
When did Mircette lose exclusivity?
Mircette lost its principal commercial exclusivity after generic manufacturers entered the U.S. market. Its current economics are therefore determined by generic competition rather than by an active branded exclusivity period.
| Exclusivity factor |
Mircette status |
| New chemical entity exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No material current effect |
| Brand-specific market protection |
Expired or commercially bypassed |
| Generic entry |
Established |
| Current pricing power |
Low |
| Current patent-driven barrier |
No material barrier identified in the active commercial market |
The product’s commercial life followed the standard lifecycle for an older small-molecule contraceptive: branded launch, generic entry, price compression, formulary substitution, and declining brand relevance.
The absence of current brand strength does not imply that every formulation-related patent expired on the same date. It means that any remaining intellectual-property rights do not appear to prevent generic competition for the marketed regimen.
What is the Orange Book status of Mircette?
Mircette was approved under an abbreviated or legacy small-molecule regulatory framework and was associated with an FDA-approved new drug application. FDA records distinguish between a product that is no longer marketed and a product withdrawn for safety or efficacy reasons.[2]
The commercial interpretation is straightforward:
- Mircette is not a current branded growth product.
- Generic products can compete through abbreviated new drug applications.
- An inactive or discontinued brand listing does not restore exclusivity.
- Orange Book patent listings, if present historically, do not create an effective current barrier when generic products are already approved and marketed.
No current revenue case should assume that Mircette has meaningful FDA exclusivity, launch exclusivity, or branded formulary protection.
How many patents protect Mircette?
Mircette’s original protection was likely based on a combination of formulation, dosing-regimen, and product patents rather than composition-of-matter protection for a new active ingredient. Desogestrel and ethinyl estradiol were established contraceptive ingredients before Mircette was introduced.
The relevant patent categories were:
| Patent category |
Commercial relevance |
| Active-ingredient patents |
Minimal because the ingredients were established compounds |
| Combination-product patents |
Potentially relevant during the branded period |
| Regimen patents |
Relevant to the reduced hormone-free interval |
| Formulation patents |
Potentially relevant to tablet composition and phased dosing |
| Manufacturing patents |
Limited value once equivalent products could be manufactured by multiple suppliers |
| Method-of-use patents |
Narrow relevance because contraception is an established use |
The patent estate is weak as a current commercial moat. Generic manufacturers have demonstrated that the formulation and regimen can be supplied without preserving Mircette’s branded economics.
A patent-number-level assessment requires a dated Orange Book and patent-family review. The commercial record does not support a conclusion that an unexpired Mircette patent currently blocks generic supply.
What formulations are protected by Mircette-related intellectual property?
The product’s main technical distinction is its phased tablet regimen. A typical pack includes:
- Active tablets containing desogestrel and ethinyl estradiol.
- A lower-dose ethinyl estradiol phase.
- Inert or non-hormonal tablets used to complete the 28-day cycle.
This design attempted to shorten the hormone-free interval while maintaining a familiar monthly dosing format. The intellectual-property value therefore rested on the combination of active ingredients, dosage sequence, and packaging presentation.
That protection was commercially vulnerable because generic manufacturers could pursue:
- The same active ingredients and strengths.
- A therapeutically equivalent phased regimen.
- Alternative packaging and tablet-color configurations.
- Abbreviated approval based on reference-product equivalence.
For established oral contraceptives, formulation patents rarely preserve premium pricing after generic approval unless they cover a clinically important delivery technology or a differentiated extended-release system. Mircette did not develop into that type of platform product.
What was Mircette’s historical financial trajectory?
No public company has consistently reported Mircette revenue as a separate line item. Organon historically marketed the product, but company disclosures generally grouped oral contraceptive products within broader women’s-health or pharmaceutical categories.
The financial trajectory can be segmented into four periods:
| Period |
Market condition |
Financial effect |
| Initial branded period |
Limited direct competition and regimen differentiation |
Higher price and stronger gross margin |
| Pre-generic maturity |
Established physician and pharmacy awareness |
Stable but aging revenue base |
| Generic-entry period |
ANDA competition and substitution |
Rapid price and volume pressure |
| Post-generic period |
Multiple suppliers and low brand visibility |
Minimal branded revenue and low strategic value |
Mircette’s revenue decline was driven by product maturity rather than by a major clinical failure. The principal mechanisms were generic substitution, lower reimbursement, formulary pressure, and migration to newer contraceptive options.
A precise revenue series is not available from public issuer reporting. Any valuation model assigning material standalone sales to Mircette would therefore rely on external prescription or channel data rather than audited company disclosures.
Which companies challenge Mircette commercially?
Mircette competes with two groups of products.
Generic desogestrel/ethinyl estradiol suppliers
Generic manufacturers can compete through abbreviated new drug applications and pharmacy substitution. The relevant competitive advantages are:
- Lowest acquisition cost.
- Reliable supply.
- National wholesaler access.
- Medicaid and commercial-plan reimbursement.
- Pharmacy benefit manager formulary status.
The product is not dependent on a single generic challenger. Competition is structurally fragmented, which limits pricing power for all suppliers.
Alternative oral contraceptives
Mircette also competes with other combined oral contraceptives, including products containing:
- Norgestimate and ethinyl estradiol.
- Levonorgestrel and ethinyl estradiol.
- Drospirenone and ethinyl estradiol.
- Norethindrone and ethinyl estradiol.
It also competes with progestin-only pills, intrauterine systems, contraceptive implants, injections, patches, and vaginal rings. Long-acting reversible contraception places the greatest structural pressure on older daily oral contraceptives because it reduces adherence burden and creates a different treatment pathway.
What generic entry risks exist for Mircette?
Generic-entry risk is no longer an emerging risk for Mircette. It is the product’s established market structure.
The principal risks are:
| Risk |
Effect on Mircette |
| Pharmacy substitution |
Removes brand demand at the point of dispensing |
| Multiple ANDA suppliers |
Reduces generic pricing |
| Formulary exclusion |
Limits branded prescriptions |
| Wholesale destocking |
Reduces channel inventory |
| Prescriber familiarity with newer options |
Lowers new-start volume |
| Supply interruptions |
Can shift share temporarily but rarely rebuild brand equity |
| OTC contraceptive expansion |
May broaden access while increasing channel competition |
The most plausible generic launch scenario is not a future branded disruption. It is continued erosion of any residual branded prescriptions, with volume distributed among generic suppliers and substitute contraceptive regimens.
What is the FDA regulatory status of Mircette?
Mircette’s regulatory status should be treated as legacy and post-exclusivity. FDA labeling establishes the product’s approved contraceptive use and provides the relevant safety framework for combined hormonal contraception, including thromboembolic, cardiovascular, hepatic, and smoking-related warnings.[1]
The product remains subject to the general regulatory requirements applicable to approved drug products, including:
- Manufacturing quality standards.
- Labeling compliance.
- Adverse-event reporting.
- Product-specific supply obligations if marketed.
- ANDA requirements for generic equivalents.
FDA approval of generic equivalents does not require a new clinical development program comparable to the original product. Generic applicants generally demonstrate pharmaceutical equivalence, bioequivalence, and compliance with applicable manufacturing requirements.
How strong is the Mircette patent estate?
The Mircette patent estate is commercially weak by current pharmaceutical standards.
Strengths
- Recognizable dosing architecture.
- Established clinical use.
- Straightforward oral tablet manufacturing.
- Regulatory familiarity.
- Potentially broad historical product recognition.
Weaknesses
- No novel active pharmaceutical ingredient.
- No biologic manufacturing barrier.
- No complex delivery device.
- Mature contraceptive market.
- Multiple therapeutic substitutes.
- Generic approvals and established substitution.
- Limited opportunity to sustain premium pricing.
Mircette has no biosimilar risk because it is a conventional small-molecule drug, not a biologic. The relevant competition is generic substitution, not biosimilar interchangeability.
What patent litigation affects Mircette?
No major current patent-litigation campaign is associated with Mircette’s commercial market. The product does not appear to be the subject of an active, high-value Paragraph IV dispute comparable to litigation involving recently launched specialty drugs.
Historical generic challenges may have involved patent certifications or product rights, but the commercial outcome is already reflected in generic availability. Patent litigation has not preserved a meaningful branded market.
A Paragraph IV certification challenges the validity, enforceability, or infringement of a listed patent. In Mircette’s case, generic market entry demonstrates that any historical patent dispute did not create a durable barrier to substitution.
What licensing deals affected Mircette?
No major current licensing transaction drives Mircette’s market value. The product originated within Organon’s women’s-health portfolio and later existed within corporate structures affected by broader pharmaceutical transactions, including the separation of Organon from Merck.
Those corporate events changed ownership and portfolio reporting but did not restore product exclusivity or create a new growth platform. Mircette’s licensing value is therefore limited. A company acquiring rights to the product would mainly obtain a legacy regulatory file, residual brand recognition, and possible supply or distribution economics.
How does Mircette compare with newer contraceptives?
| Factor |
Mircette |
Newer contraceptive products |
| Daily adherence burden |
High |
Often lower for long-acting products |
| Generic availability |
Established |
Varies |
| Patent protection |
Weak or expired |
May be active |
| Manufacturing complexity |
Low |
Can be higher for devices or extended-release systems |
| Pricing power |
Low |
Higher when protected |
| Prescriber differentiation |
Limited |
May include tolerability or convenience claims |
| Commercial growth potential |
Low |
Higher for protected products |
| Payer leverage |
Strong |
Depends on rebates and coverage |
Mircette can retain use among patients who prefer its regimen or have prior experience with it, but that loyalty is unlikely to support substantial branded revenue.
What revenue exposure remains?
Mircette’s remaining economic exposure is concentrated in:
- Generic manufacturing contracts.
- Authorized-generic arrangements.
- Residual brand prescriptions.
- Wholesale and pharmacy distribution.
- Regulatory-file ownership.
- International markets where generic substitution is less developed.
The revenue profile is likely low-margin and volume-dependent. It has limited capacity to support a high-growth pharmaceutical valuation. Any investment thesis would need to rely on broader portfolio economics, manufacturing scale, or cross-selling rather than Mircette alone.
Key Takeaways
- Mircette is a legacy combined oral contraceptive containing desogestrel and ethinyl estradiol.
- Its principal commercial protection has ended, and generic competition is established.
- No meaningful current Mircette-specific exclusivity or patent moat supports premium pricing.
- Kariva and generic desogestrel/ethinyl estradiol products are the main direct substitutes.
- The product has no biosimilar risk because it is a small-molecule drug.
- Public companies do not generally disclose standalone Mircette revenue.
- Financial value has shifted from branded sales to residual generic, supply, and distribution economics.
- The principal long-term risks are generic price compression, formulary exclusion, and migration to long-acting or newer contraceptive options.
- Mircette is unlikely to produce material standalone growth without a new commercial strategy, reformulation, or channel expansion.
FAQs About Mircette Market and Exclusivity
Is Mircette still available in the United States?
The original brand has limited commercial relevance, while generic desogestrel/ethinyl estradiol products and the Kariva brand have served the same market.
Is Kariva the same as Mircette?
Kariva uses the same principal active ingredients and a substantially comparable phased oral-contraceptive regimen. Product-specific labeling and inactive ingredients may differ.
Can a generic manufacturer launch Mircette without a clinical trial?
A generic manufacturer generally uses the FDA abbreviated new drug application pathway, which relies on pharmaceutical equivalence and bioequivalence rather than a full new clinical-efficacy program.
Does Mircette have an active composition-of-matter patent?
The active ingredients are established contraceptive compounds. Mircette’s historical protection was principally associated with the product combination, dosing regimen, and formulation rather than a new chemical entity patent.
Is Mircette a potential acquisition target?
Mircette alone is unlikely to justify a strategic acquisition at a high valuation. Its potential value would be tied to a broader portfolio, low-cost manufacturing platform, authorized-generic strategy, or access to specific distribution channels.
References
- U.S. Food and Drug Administration. (n.d.). Mircette prescribing information. FDA labeling database.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (n.d.). Discontinued drugs database. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products and abbreviated new drug applications. FDA.
- Centers for Disease Control and Prevention. (2024). U.S. medical eligibility criteria for contraceptive use. U.S. Department of Health and Human Services.
